Literature DB >> 21516176

Chronic benzodiazepine treatment does not alter interactions between positive GABA(A) modulators and flumazenil or pentylenetetrazole in monkeys.

Lisa R Gerak1, Charles P France.   

Abstract

Benzodiazepines and neuroactive steroids are positive c-aminobutyric acid(A) (GABA(A)) modulators acting at distinct binding sites; during benzodiazepine treatment, tolerance develops to many behavioral effects of benzodiazepines, although cross tolerance typically does not develop to neuroactive steroids. To determine whether differential changes in binding sites contribute to these behavioral differences, interactions between GABA(A) modulators were studied in two groups of four monkeys: one otherwise untreated group discriminated 0.178 mg/kg of the benzodiazepine midazolam; the other received 5.6 mg/kg/day of diazepam and discriminated 0.1 mg/kg of flumazenil, which binds to benzodiazepine sites without modulating GABA(A) receptors. In untreated monkeys, flumazenil antagonized midazolam but not the neuroactive steroid pregnanolone, whereas pentylenetetrazole (a negative modulator acting at a third site) antagonized both positive modulators. In diazepam-treated monkeys, 0.1 mg/kg of flumazenil or 32 mg/kg of pentylenetetrazole produced flumazenil-lever responding, which was reversed by midazolam and pregnanolone. As the flumazenil dose increased, larger doses of midazolam, but not pregnanolone, were needed to reverse flumazenil-lever responding. When the pentylenetetrazole dose increased, larger doses of both positive modulators were needed. Thus, interactions between GABA(A) modulators were not different between diazepam-treated and untreated monkeys and do not reveal changes in binding sites that could account for reported differences between benzodiazepines and neuroactive steroids.

Entities:  

Keywords:  GABAA modulators; diazepam; drug discrimination; flumazenil; monkey; monkeys; neuroactive steroids; pentylenetetrazole; pregnanolone

Mesh:

Substances:

Year:  2011        PMID: 21516176      PMCID: PMC3080037          DOI: 10.1097/FBP.0b013e3283425aa0

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  25 in total

1.  Acute and chronic effects of the neuroactive steroid pregnanolone on schedule-controlled responding in rhesus monkeys.

Authors:  L R McMahon; C P France
Journal:  Behav Pharmacol       Date:  2002-11       Impact factor: 2.293

2.  Discriminative stimulus effects of flumazenil in untreated and in diazepam-treated rhesus monkeys.

Authors:  L R Gerak; C P France
Journal:  Psychopharmacology (Berl)       Date:  1999-10       Impact factor: 4.530

3.  Regional GABA/benzodiazepine receptor/chloride channel coupling after acute and chronic benzodiazepine treatment.

Authors:  E I Tietz; T H Chiu; H C Rosenberg
Journal:  Eur J Pharmacol       Date:  1989-08-11       Impact factor: 4.432

4.  Discriminative-stimulus effects of triazolam and midazolam in rhesus monkeys.

Authors:  S Lelas; L R Gerak; C P France
Journal:  Behav Pharmacol       Date:  1999-02       Impact factor: 2.293

5.  gamma-Aminobutyric acid agonists and antagonists alter chloride flux across brain membranes.

Authors:  A M Allan; R A Harris
Journal:  Mol Pharmacol       Date:  1986-05       Impact factor: 4.436

6.  Daily treatment with diazepam differentially modifies sensitivity to the effects of gamma-aminobutyric acid(A) modulators on schedule-controlled responding in rhesus monkeys.

Authors:  Lance R McMahon; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2002-03       Impact factor: 4.030

7.  Antagonism of the discriminative stimulus effects of positive gamma-aminobutyric acid(A) modulators in rhesus monkeys discriminating midazolam.

Authors:  S Lelas; L R Gerak; C P France
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

8.  Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself.

Authors:  D S Reddy; M A Rogawski
Journal:  J Pharmacol Exp Ther       Date:  2000-12       Impact factor: 4.030

9.  Time course for development of anticonvulsant tolerance and GABAergic subsensitivity after chronic diazepam.

Authors:  S F Gonsalves; D W Gallager
Journal:  Brain Res       Date:  1987-03-03       Impact factor: 3.252

10.  Effects of continuous diazepam administration on GABAA subunit mRNA in rat brain.

Authors:  C Heninger; N Saito; J F Tallman; K M Garrett; M P Vitek; R S Duman; D W Gallager
Journal:  J Mol Neurosci       Date:  1990       Impact factor: 3.444

View more
  5 in total

1.  Quantitative analyses of antagonism: combinations of midazolam and either flunitrazepam or pregnanolone in rhesus monkeys discriminating midazolam.

Authors:  Lisa R Gerak; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2011-12-15       Impact factor: 4.030

2.  Quantitative pharmacological analyses of the interaction between flumazenil and midazolam in monkeys discriminating midazolam: Determination of the functional half life of flumazenil.

Authors:  Claudio Zanettini; Charles P France; Lisa R Gerak
Journal:  Eur J Pharmacol       Date:  2013-11-08       Impact factor: 4.432

3.  Differential interactions engendered by benzodiazepine and neuroactive steroid combinations on schedule-controlled responding in rats.

Authors:  Barak W Gunter; Donna M Platt; James K Rowlett
Journal:  Pharmacol Biochem Behav       Date:  2015-08-06       Impact factor: 3.533

4.  Acute tolerance to chlordiazepoxide qualitatively changes the interaction between flumazenil and pregnanolone and not the interaction between flumazenil and midazolam in rhesus monkeys discriminating midazolam.

Authors:  Claudio Zanettini; Seong Shoon Yoon; Charles P France; Lisa R Gerak
Journal:  Eur J Pharmacol       Date:  2013-01-07       Impact factor: 4.432

5.  Discriminative stimulus effects of pregnanolone in rhesus monkeys.

Authors:  Lisa R Gerak; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2013-08-15       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.